10-KPeriod: FY2021

Medtronic plc Annual Report, Year Ended Apr 30, 2021

Filed June 25, 2021For Securities:MDT

Summary

Medtronic plc's 2021 10-K filing indicates a company navigating the complexities of the COVID-19 pandemic while focusing on strategic growth and operational efficiency. The company reported a total net sales increase of 4% to $30.1 billion, driven by a recovery in medical procedure volumes globally as pandemic restrictions eased, although recovery was uneven across geographies and product lines. Key segments like Cardiovascular and Medical Surgical showed modest growth, while Neuroscience saw a 6% increase. The Diabetes unit experienced a 2% rise in sales. Medtronic emphasized its commitment to innovation and leveraging technology, including AI and data analytics, to tailor therapies and improve patient care. The company also highlighted its ongoing restructuring efforts, including the 'Enterprise Excellence' program and a new 'Simplification' initiative aimed at streamlining operations and enhancing competitiveness. Despite global economic uncertainties and competitive pressures, Medtronic maintained a strong financial position, with significant cash reserves and a robust credit facility, underscoring its resilience and ability to invest in future growth and shareholder returns.

Financial Highlights

54 data points
Beta

Revenue

$30.12B

65.2% Gross Margin

Net Income

$3.63B

12.1% Net Margin

EPS (Diluted)

$2.66

Total Assets

$93.08B

Cash & Equivalents

$3.59B

Free Cash Flow

$4.88B

Financial Statements
Beta
Revenue$30.12B
Cost of Revenue$10.48B
Gross Profit$19.63B
SG&A Expenses$10.15B
Operating Income$4.48B
Interest Expense$925.00M
Net Income$3.63B
EPS (Basic)$2.68
EPS (Diluted)$2.66
Shares Outstanding (Basic)1.34B
Shares Outstanding (Diluted)1.35B

Key Highlights

  • 1Total net sales increased by 4% to $30.1 billion, reflecting a recovery in global medical procedure volumes post-COVID-19.
  • 2The Cardiovascular segment saw a 3% increase in net sales to $10.8 billion, driven by Cardiac Rhythm & Heart Failure products, though Structural Heart & Aortic was flat and Coronary & Peripheral Vascular declined.
  • 3Medical Surgical segment net sales grew by 5% to $8.7 billion, largely due to a strong performance in Respiratory, Gastrointestinal, & Renal products, boosted by COVID-19 related demand.
  • 4Neuroscience segment sales increased by 6% to $8.2 billion, with growth across all divisions, supported by the recovery in procedure volumes.
  • 5The company reported Non-GAAP diluted earnings per share of $4.44, an improvement from the previous fiscal year, indicating effective management of operational performance.
  • 6Medtronic maintained a strong liquidity position with $3.6 billion in cash and cash equivalents and $7.2 billion in current investments, alongside a $3.5 billion credit facility.
  • 7Significant restructuring efforts, including the 'Enterprise Excellence' and 'Simplification' programs, are underway to drive long-term efficiency and competitiveness, with associated charges noted.

Frequently Asked Questions

Medtronic reported a 4% increase in total net sales to $30.1 billion for fiscal year 2021. This growth was primarily driven by the recovery of medical procedure volumes globally as pandemic-related restrictions eased, although the recovery was uneven across different regions and product lines. Despite the ongoing impact of COVID-19, the company demonstrated resilience, with improved Non-GAAP diluted earnings per share of $4.44.

In the Cardiovascular segment, Cardiac Rhythm & Heart Failure products, including the Micra leadless pacing system, drove growth. However, Structural Heart & Aortic sales were flat, impacted by a product recall, and Coronary & Peripheral Vascular sales declined due to pricing pressures in China. The Medical Surgical segment saw strength in Respiratory, Gastrointestinal, & Renal products, partly due to COVID-19 demand, while Surgical Innovations experienced a slight decline. The Neuroscience segment showed growth across its divisions, benefiting from procedural recovery. The Diabetes segment experienced modest growth, with strength in international markets for the MiniMed 780G system.

Medtronic is undertaking significant restructuring initiatives. The 'Enterprise Excellence' program aims to drive long-term growth and efficiency through optimizing global operations, functions, and commercial processes, with projected gross savings of over $3 billion. Additionally, the 'Simplification' program is streamlining the organizational structure into a portfolio-level model with empowered operating units to accelerate decision-making and enhance competitiveness, targeting annual savings of approximately $450 million to $475 million.

Medtronic maintains a strong liquidity position with $3.6 billion in cash and cash equivalents and $7.2 billion in current investments as of April 30, 2021. The company also has access to a $3.5 billion credit facility. Total debt increased to $26.4 billion, primarily due to the issuance of Euro-denominated senior notes and debt redemptions. Despite the debt levels, the company's credit ratings remain strong, and management believes its liquidity sources and cash flow generation capabilities are sufficient to meet its foreseeable operating needs and capital allocation strategies.